AIM2 and melanoma: In contrast, AIM2 upregulation promoted cell growth, metastasis and immunosuppression through the inflammasome-dependent pathway and correlated with poor survival in non-small cell lung cancer [13, 14], melanoma [15] and triple-negative breast cancer [16].